相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trends of stomach cancer mortality in Eastern Asia in 1950-2004: comparative study of Japan, Hong Kong and Singapore using age, period and cohort analysis
Masahiro Tanaka et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer
Jung A. Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
M. J. A. de Jonge et al.
EUROPEAN JOURNAL OF CANCER (2011)
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
M. Moehler et al.
EUROPEAN JOURNAL OF CANCER (2011)
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Yung-Jue Bang et al.
INVESTIGATIONAL NEW DRUGS (2011)
Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Jesus Garcia-Donas et al.
LANCET ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008
Kyu-Won Jung et al.
CANCER RESEARCH AND TREATMENT (2011)
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
Francisco Robert et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Docetaxel: its role in current and future treatments for advanced gastric cancer
Masahiko Nishiyama et al.
GASTRIC CANCER (2009)
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
Nielka P. van Erp et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer
Haijun Zhong et al.
ANTI-CANCER DRUGS (2008)
A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy
Jae-Lyun Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
Carolyn D. Britten et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer
Carlo Barone et al.
GASTRIC CANCER (2007)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
Anna D. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen
SH Park et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2004)
Rhebbing up mTOR - New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis
DJ Kwiatkowski
CANCER BIOLOGY & THERAPY (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer:: a phase II trial
YJ Bang et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
